EcoDrugPlus

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSPKIG00000022380
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSPKIG00000020632
Gene Symbol: OPRD1
3 Cross references
251 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSPKIG00000005182
Gene Symbol: OPRK1
4 Cross references
197 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSPKIG00000018694
Gene Symbol: OPRL1
4 Cross references
131 Possible Orthologues:

Oxysterols Receptor Lxr-Alpha-Like

Ensembl ID : ENSPKIG00000006820
Gene Symbol: LOC111851925
3 Cross references
389 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSPKIG00000024683
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSPKIG00000007192
Gene Symbol: PAK4
3 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSPKIG00000005707
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Permeability Factor 2-Like

Ensembl ID : ENSPKIG00000016310
Gene Symbol: LOC111836793
3 Cross references
182 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSPKIG00000021739
Gene Symbol: PPARA
4 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSPKIG00000022095
Gene Symbol: PPARA
4 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSPKIG00000016280
Gene Symbol: PPARD
3 Cross references
351 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).